Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
02297 RAINMED-B
1.250-0.050-3.85%
Closed
02/03 16:08 CCT
High
1.340
Open
1.290
Turnover
194.45K
Low
1.250
Pre Close
1.300
Volume
153.00K
Price Forecast
News
Comment
Rainmed's Coronary Assessment Products Added to Chinese Expert Consensus
08:52 AM EST, 12/29/2022 (MT Newswires) -- Two of Rainmed Medical's (HKG:2297) core products, caFFR and caIMR, have been included in the Chinese expert consensus on the computation of coronary physiol
Run Mead-B: interim report 2022
Run Meade-B: interim results announcement for the six months ended June 30, 2022
Run Meade-B: date of the board meeting
Rainmed Gets Additional Funds from Partial Exercise of Hong Kong IPO's Overallotment; Shares Slip 4%
02:46 AM EDT, 08/01/2022 (MT Newswires) -- Rainmed Medical (HKG:2297) said the overallotment option of its initial public offering in Hong Kong was partially exercised by its underwriters on July 30.
Hong Kong Stocks End Higher; Xuan Wu Cloud Ekes Out Gain as Rainmed, Lushang Fall on Debut
05:29 AM EDT, 07/08/2022 (MT Newswires) -- Hong Kong stocks gained for a second day to conclude the week slightly higher, on optimism that the further reopening of the city would boost recovery, while
Rainmed Fails to Make Splash in Hong Kong Debut as Shares Fall 10% at Open
09:56 PM EDT, 07/07/2022 (MT Newswires) -- Shares of Rainmed Medical (HKG:2297) dropped over 10% on their maiden trading in Hong Kong Friday morning, an indication that newly-listed companies in the c
Ping An-Backed Rainmed Prices Hong Kong IPO at Top of Range, Raises $10 Million
11:12 PM EDT, 07/06/2022 (MT Newswires) -- Rainmed Medical (HKG:2297) raised HK$78.9 million ($10 million) in net proceeds from its initial public offering in Hong Kong after pricing the shares at the
RAINMED-B (02297.HK) Priced at Upper End at $6.24; One-lot Success Rate 20%
RAINMED-B (02297.HK) announced that the offer price has been determined at $6.24 per share, which was the upper end of its listing price range ($4.28-6.24). The Hong Kong public offering was oversubsc
No More
Company Overview
More
Founded in 2014, Runmide Medical Group strives to become the world's leading intervascular surgery robot company. Currently, it focuses on the design, development and commercialization of coronary angiography blood flow reserve score (CAFFR) systems and coronary angiography microvascular resistance index (caMR) systems. Runmide Healthcare innovates and is proactive, gradually weaving into a global R&D, production, sales and service network.
RunMed Healthcare has actively cooperated with top medical centers and experts at home and abroad to establish a complete patent system, and many research results have continued to be published in authoritative magazines such as “Immunity Research” and “JACC: Anomalous Disorders”. Furthermore, the company has signed strategic cooperation agreements with many top medical device distribution service platforms in China, formulated strict quality inspection systems and perfect supply processes, and successfully passed medical device quality management system certification.
In the future, Runmide Medical will adhere to the purpose of “shaping precision medicine and serving the health of all”, rely on technological accumulation in control algorithms, image navigation, image intelligence, evidence-based medicine, etc., launch interventional surgical robots, and gradually build unmanned operating rooms to enhance the clinical value of products and create a new situation of precision medicine in the field of intervention.
CEO： Yunfei Huo
Market： Hong Kong motherboard
Listing Date： 07/08/2022
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet